 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  CapitalBio and Affymetrix to Support and Promote Rice Functional Genomic Research in ChinaPress Release October 11, 2005 BEIJING & SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 10, 2005--CapitalBio Corporation, a leading life science company based in Beijing, P.R. China, and Affymetrix Inc. (Nasdaq:AFFX) announced plans to laun ch an initiative to support and promote rice functional genomic research in China. Under the initiative, CapitalBio, as an Affymetrix authorized service provider in China, will provide Affymetrix GeneChip(R) Rice Genome Array services to the Chinese Rice Functional Genomic Research Consortium (CRFGRC), which consists of more than a dozen top research institutes, National Key Laboratories and universities. Rice is the most important crop for human consumption and provides staple food for more than half of the world's population. China possesses the largest rice-producing land area in the world. Its rice output accounts for about half of the country's total grain yield. China has a long history in rice cultivation and has accumulated vast experience in rice breeding. Affymetrix GeneChip technology enables researchers to monitor the gene expression profiles across the entire rice genome. This information provides scientists with a better understanding about the plant physiology, development, genetics and evolution. "Traditionally, China is an agricultural country, and rice research is one of the most important areas of agricultural research in China," commented Professor Yongbiao Xue, Co-Chair of CRFGRC and the Director of the Institute of Genetics and Development Biology, Chinese Academy of Sciences. "I am pleased that CapitalBio and Affymetrix have committed to providing more affordable rice microarrays. The results derived from the research should provide valuable information on our understanding of the rice genome and insights on how to improve rice yield and quality." "Researchers at the CRFGRC are using GeneChip technology to perform breakthrough science that will increase our understanding of the genomic functions of rice, the world's most important crop," said Mitchell Kennedy, Vice President of Global Technical Support and General Manager of International Trading Business Unit at Affymetrix. "We are engaged with leading life science companies such as CapitalBio to accelerate genomic research and improve the quality of life." "CapitalBio has been providing Biochip products and services to the scientific community in China and beyond, and Affymetrix' GeneChip technology has been widely adopted in life science research around the world," said David Sun, Senior Vice President of CapitalBio. "CapitalBio is delighted to provide Affymetrix' high quality GeneChip-based services to the Chinese Rice Functional Genomic Research Consortium. The Affymetrix GeneChip technology complements CapitalBio's products and services nicely and completes our total offering to the research community, including CRFGRC. We are proud to be part of this collective effort in driving advanced research on the rice genome." In April 2005, Affymetrix and CapitalBio entered into joint R&D and commercialization programs, and announced plans to collaborate on promoting and advancing standards on microarray technologies, products and industrial processes. About CapitalBio CapitaBio is a leading life science Company that develops and commercializes a broad range of products, including Biochip technology products, for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive life science entity with five affiliates or subsidiaries: AVIVA Biosciences, a San Diego, California based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a Biotech company located in Shenzhen, China, for small molecular drug discovery and development; Wangdong Medical Equipment, one of the largest medical equipment companies in China that occupies about 70% of China's conventional X-Ray imaging market; and CapitalBio International and CapitalBio Hong Kong, two fully owned subsidiaries by CapitalBio Corporation, are based at San Diego, California and Hong Kong, China respectively. Additional information on CapitalBio can be found at www.capitalbio.com. About Affymetrix Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development (including uncertainties relating to commercial and technological success of the strategic alliance between CapitalBio, the Chinese Rice Functional Genomic Research Consortium and Affymetrix discussed in this press release), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2004 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. Contacts Affymetrix Wes Conard, 408-731-5791 wes_conard@affymetrix.com or CapitalBio David Sun, (86 10) 8072 6868 x 8311 (CHINA) 805-300-5155 (USA) dsun@capitalbio.com
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page